1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Enasidenib
Trade Name:
IDHIFA
Manufacturer/Distributor:
Celgene Inc.
Classification:
Antineoplastic agent / IDH2 Inhibitor
ATC Class:
L01XX59 - enasidenib
Status:
active
Notice of Compliance (yyyy/mm/dd):
2019/02/06
Date Marketed in Canada (yyyy/mm/dd):
2019/02/27
Presentation:
Tablet: 50 mg. DIN: 02485427
Tablet: 100 mg. DIN: 02485435
Comments:
Notice of compliance with conditions (NOC/C).
For treatment of adults with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation.
Back to:
Drug Product Listings 
